No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $70
Incyte Price Target Raised to $70 From $68 at Wells Fargo
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)
Incyte Analyst Ratings